Medical Affairs Plans. NVS will prepare a reasonably detailed, annual plan for global Medical Affairs with respect to In-Vivo [***] Products (the “Global Medical Affairs Plan”), and HMI will prepare a reasonably detailed, annual plan for Medical Affairs with respect to In-Vivo [***] Products in the U.S. (the “U.S. Medical Affairs Plan”), in each case, no later than [***] for an In-Vivo [***] Product. The strategic objectives in the U.S. Medical Affairs Plan will be consistent with the strategic objectives in the Global Medical Affairs Plan, unless otherwise agreed by the Parties. In order to ensure consistency between the Global Medical Affairs Plan and the U.S. Medical Affairs Plan and coordination and alignment between the Parties with respect to the Medical Affairs to be conducted by NVS with respect to In-Vivo [***] Products pursuant to the Global Medical Affairs Plan and by HMI with respect to U.S. [***] Products pursuant to the U.S. Medical Affairs Plan (including with respect to each Party’s communications with key opinion leaders in the Territory), the Global Medical Affairs Plan and the U.S. Medical Affairs Plan, and any material amendments or updates thereto will be reviewed and discussed by the JSC, with the first such review and discussion occurring no later than [***] for an In-Vivo [***] Product. Any subsequent review and discussion, to the extent required, will occur annually thereafter at an appropriate time as agreed by the JSC, or more frequently as may be required during the Term.
Appears in 3 contracts
Samples: Collaboration and License Agreement (Homology Medicines, Inc.), Collaboration and License Agreement (Homology Medicines, Inc.), Collaboration and License Agreement (Homology Medicines, Inc.)
Medical Affairs Plans. NVS will prepare a reasonably detailed, annual plan for global Medical Affairs with respect to In-Vivo [***] SCD Products (the “Global Medical Affairs Plan”), and HMI will prepare a reasonably detailed, annual plan for Medical Affairs with respect to In-Vivo [***] SCD Products in the U.S. (the “U.S. Medical Affairs Plan”), in each case, no later than [***] for or an In-Vivo [***] SCD Product. The strategic objectives in the U.S. Medical Affairs Plan will be consistent with the strategic objectives in the Global Medical Affairs Plan, unless otherwise agreed by the Parties. In order to ensure consistency between the Global Medical Affairs Plan and the U.S. Medical Affairs Plan and coordination and alignment between the Parties with respect to the Medical Affairs to be conducted by NVS with respect to In-Vivo [***] SCD Products pursuant to the Global Medical Affairs Plan and by HMI with respect to U.S. [***] SCD Products pursuant to the U.S. Medical Affairs Plan (including with respect to each Party’s communications with key opinion leaders in the Territory), the Global Medical Affairs Plan and the U.S. Medical Affairs Plan, and any material amendments or updates thereto will be reviewed and discussed by the JSC, with the first such review and discussion occurring no later than [***] for an In-Vivo [***] SCD Product. Any subsequent review and discussion, to the extent required, will occur annually thereafter at an appropriate time as agreed by the JSC, or more frequently as may be required during the Term.
Appears in 1 contract
Samples: Collaboration and License Agreement (Homology Medicines, Inc.)